EP4247364A4 - Zusammensetzungen zur verbesserten abgabe von cgrp-inhibitoren - Google Patents

Zusammensetzungen zur verbesserten abgabe von cgrp-inhibitoren Download PDF

Info

Publication number
EP4247364A4
EP4247364A4 EP21895549.0A EP21895549A EP4247364A4 EP 4247364 A4 EP4247364 A4 EP 4247364A4 EP 21895549 A EP21895549 A EP 21895549A EP 4247364 A4 EP4247364 A4 EP 4247364A4
Authority
EP
European Patent Office
Prior art keywords
compositions
improved delivery
cgrp inhibitors
cgrp
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21895549.0A
Other languages
English (en)
French (fr)
Other versions
EP4247364A1 (de
Inventor
Charles M. CONWAY
Gene M. Dubowchik
Rajesh Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ireland Pharmaceuticals
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of EP4247364A1 publication Critical patent/EP4247364A1/de
Publication of EP4247364A4 publication Critical patent/EP4247364A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
EP21895549.0A 2020-11-19 2021-11-18 Zusammensetzungen zur verbesserten abgabe von cgrp-inhibitoren Pending EP4247364A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115789P 2020-11-19 2020-11-19
US202063126550P 2020-12-17 2020-12-17
PCT/US2021/059801 WO2022109077A1 (en) 2020-11-19 2021-11-18 Compositions for improved delivery of cgrp inhibitors

Publications (2)

Publication Number Publication Date
EP4247364A1 EP4247364A1 (de) 2023-09-27
EP4247364A4 true EP4247364A4 (de) 2024-10-23

Family

ID=81709748

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21895549.0A Pending EP4247364A4 (de) 2020-11-19 2021-11-18 Zusammensetzungen zur verbesserten abgabe von cgrp-inhibitoren

Country Status (9)

Country Link
EP (1) EP4247364A4 (de)
JP (1) JP2023551146A (de)
KR (1) KR20230088442A (de)
AU (1) AU2021385052A1 (de)
CA (1) CA3202137A1 (de)
IL (1) IL302948A (de)
MX (1) MX2023005846A (de)
WO (1) WO2022109077A1 (de)
ZA (1) ZA202304727B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115154469A (zh) * 2022-07-22 2022-10-11 中国科学院广州生物医药与健康研究院 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用
CN117503704B (zh) * 2023-11-09 2025-07-11 广州新济药业科技有限公司 一种作用于中枢神经系统的鼻喷雾剂及其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127328A1 (en) * 2019-01-20 2020-07-23 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
CA3136485A1 (en) * 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
WO2015120014A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
RU2019123406A (ru) * 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
KR102444717B1 (ko) * 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
WO2021062282A1 (en) * 2019-09-25 2021-04-01 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists
CN114980862A (zh) * 2019-12-17 2022-08-30 拜尔哈文制药股份有限公司 Cgrp抑制剂的鼻内药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127328A1 (en) * 2019-01-20 2020-07-23 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
CA3136485A1 (en) * 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MERCER STEPHEN E ET AL: "Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 31, 21 October 2020 (2020-10-21), XP086408197, ISSN: 0960-894X, [retrieved on 20201021], DOI: 10.1016/J.BMCL.2020.127624 *
See also references of WO2022109077A1 *

Also Published As

Publication number Publication date
JP2023551146A (ja) 2023-12-07
ZA202304727B (en) 2023-12-20
MX2023005846A (es) 2023-06-02
AU2021385052A9 (en) 2024-05-02
KR20230088442A (ko) 2023-06-19
AU2021385052A1 (en) 2023-06-01
CA3202137A1 (en) 2022-05-27
WO2022109077A1 (en) 2022-05-27
EP4247364A1 (de) 2023-09-27
IL302948A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
EP4058032A4 (de) Zusammensetzungen zur verabreichung von antisense-verbindungen
EP4069212A4 (de) Inhibitoren von hif-2alpha
EP4263571A4 (de) Zusammensetzungen zur verbesserten abgabe von cgrp-inhibitoren
IL289534A (en) Parp1 inhibitors
EP3911409A4 (de) Cgrp-antagonisten zur behandlung eines migräne-durchbruchs
EP4076395A4 (de) Intranasale pharmazeutische zusammensetzungen von cgrp-inhibitoren
EP4217477A4 (de) Zusammensetzungen und verfahren zur hemmung der genexpression
EP3765058A4 (de) Verfahren und zusammensetzungen zur induzierbaren expression von neurotrophen faktoren
EP4415708A4 (de) Zusammensetzungen zur verabreichung von cannabinoiden
EP3801500A4 (de) Inhibitoren von sarm1
IL277778B (en) Bcl6 inhibitors
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
EP4333821A4 (de) Inhibitoren von sars-cov-2
EP4048785A4 (de) Zusammensetzungen zur drg-spezifischen reduktion der transgenexpression
EP4247364A4 (de) Zusammensetzungen zur verbesserten abgabe von cgrp-inhibitoren
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EP4225310A4 (de) Heteroarylamidinhibitoren von cd38
EP3908288A4 (de) Rnai-mittel zur hemmung der expression von hif-2 typ (epas1), zusammensetzungen davon und verwendungsverfahren
EP4041208A4 (de) Zusammensetzungen von cannabinoiden zur verabreichung durch inhalation
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EP4284511C0 (de) Azachinoline als inhibitoren von cd38
EP4416131A4 (de) Ras-hemmer, zusammensetzungen und verfahren zur verwendung davon
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3777893A4 (de) Verwendung von bis-iminobiotin-verbindung für wirkstofffreisetzungszwecke

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240924

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20240918BHEP

Ipc: A61K 9/20 20060101ALI20240918BHEP

Ipc: A61K 47/26 20060101ALI20240918BHEP

Ipc: A61K 31/551 20060101ALI20240918BHEP

Ipc: A61K 31/47 20060101ALI20240918BHEP

Ipc: A61K 31/445 20060101ALI20240918BHEP

Ipc: A61K 31/435 20060101ALI20240918BHEP

Ipc: A61K 31/416 20060101AFI20240918BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN